AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02662634
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.
Trial: NCT02662634
Drug: Abraxane
RxNorm normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
Trial: NCT02662634
Drug: Alimta
RxNorm normalized name: Alimta
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
Trial: NCT02662634
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
Trial: NCT02662634
Drug: Taxol
RxNorm normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
Trial: NCT02887573
Drug: Free-residue nutrients
RxNorm normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
Trial: NCT02887573
Drug: Low fiber diet
RxNorm normalized name: fiber
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
Trial: NCT02887573
Drug: 2L PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2L PEG are laxatives for experiment group.
Trial: NCT02887573
Drug: 4L PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4L PEG are laxatives in the control group.
Trial: NCT02887573
Drug: PEG
RxNorm normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
Trial: NCT02887573
Drug: Mosapride citrate
RxNorm normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg mosapride citrate are used to promote gastric motivity.
Trial: NCT00678080
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
Trial: NCT00678080
Drug: Insulin (NPH and Regular)
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
Trial: NCT03360747
Drug: AKCEA-ANGPTL3-LRx
RxNorm normalized name: Akcea ttr lrx
DrugBank: Eplontersen (DB16199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKCEA-ANGPTL3-LRx at dose 20 mg, administered via SC injection QW.
Trial: NCT03745924
Drug: Nonacog beta pegol
RxNorm normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
Trial: NCT00216892
Drug: Calcipotriol, (calcipotriol + betamethasone)
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03569046
Drug: local anaesthetic injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ear block by 0.25% bupivacaine
Trial: NCT00388882
Drug: tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00388882
Drug: ipratropium bromide / albuterol
RxNorm normalized name: Combivent 20/100 (ipratropium bromide / albuterol) Metered Dose Inhalation Spray, 120 ACTUAT
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04341350
Drug: Propofol + analgesic drug
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sedation according to a written, standardized Nurse management protocol using at least one sedative drug (propofol) and one analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl
Trial: NCT04341350
Drug: Isoflurane + analgesic drug
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sedation by inhalation of halogenated gas (Isoflurane) delivered by the Anesthetic-Conserving Device (ACD) system ANACONDA ™ associated with the administration of a analgesic drug. It uses the nurse driven analgesia protocol of each ward involved in the study. It uses a pain assessment score (BPS, VICOMORE, FLACC), local or regional anesthesia, non-opioïd adjuncts (acetaminophen, NSAIDs, nefopam), opioïds (per os opioïds, bolus of sufentanyl followed by continuous infusion if necessary, continuous infusion of remifentanyl.
Trial: NCT03886766
Drug: Hot-melt extruded amorphous solid dispersion of Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
Trial: NCT03886766
Drug: Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
Trial: NCT03886766
Drug: Efavirenz solution
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz solution, 3 mg, oral administration (product 3)
Trial: NCT00254397
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
Trial: NCT03148275
Drug: Trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03730012
Drug: gilteritinib
RxNorm normalized name: Gilteritinib
DrugBank: Gilteritinib (DB12141)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet
Trial: NCT03730012
Drug: atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous infusion
Trial: NCT04268550
Drug: Selpercatinib
RxNorm normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02883192
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zofran 4 mg.
Trial: NCT00884377
Drug: Sodium stibogluconate (Pentostam)
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous 20 mg/kg/day for 10 days
Trial: NCT01070758
Drug: Lanreotide autogel
DrugBank: Lanreotide (DB06791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
Trial: NCT01397201
Drug: BI 54903
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 54903
Trial: NCT01397201
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate
Trial: NCT01887340
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: - carboplatine: Dose (mg) = AUC x (GFR + 25)~* GFR : glomérulaire filtration (ml/min)~* AUC : area under curve (mg/ml x min)
Trial: NCT02905253
Drug: AC-084
RxNorm normalized name: TSN-084
DrugBank: TSN-084 (DB18306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
Trial: NCT02294084
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
Trial: NCT00780013
Drug: metformin hydrochloride liquid 500 mg per 5 mL
RxNorm normalized name: metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00343876
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00343876
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01887340
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2 D1 to D5
Trial: NCT01887340
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 de D1 to D5
Trial: NCT00000612
Drug: estrogens, conjugated
RxNorm normalized name: ESTROGENS, CONJUGATED
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03280537
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
Trial: NCT01964131
Drug: D961H sachet 20 mg
RxNorm normalized name: fosfomycin
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg
Trial: NCT00646906
Drug: Aspirin First
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crossover period Aspirin First: Subjects will receive 81 mg aspirin at approximately 8 am followed by acetaminophen at approximately 10 am.
Trial: NCT00003782
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
Trial: NCT02002247
Drug: sodium selenite
RxNorm normalized name: Sodium selenite
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
Trial: NCT02395016
Drug: nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Trial: NCT02395016
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
Trial: NCT02646475
Drug: Angiotensin-(1-7)
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
Trial: NCT02646475
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal saline will be used as a placebo comparator.
Trial: NCT03852472
Drug: Avacopan
RxNorm normalized name: Avacopan
DrugBank: Avacopan (DB15011)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Active treatment
Trial: NCT04439175
Drug: Taselisib
RxNorm normalized name: Taselisib
DrugBank: Taselisib (DB12108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00792077
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg daily for 56 days.
Trial: NCT03956134
Drug: Tapentadol Test Product 1
RxNorm normalized name: tapentadol Oral Product
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
Trial: NCT03956134
Drug: Tapentadol Test Product 2
RxNorm normalized name: tapentadol Oral Product
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
Trial: NCT03956134
Drug: Tapentadol Prolonged-release Reference Product
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
Trial: NCT01966731
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
Trial: NCT03705585
Drug: Vaxchora
RxNorm normalized name: Vaxchora
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose. Approximately 100 mL of cool or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
Trial: NCT00408538
Drug: UC-781 microbicide gel (0.1% and 0.25%)
RxNorm normalized name: Astri-UC
DrugBank: UC-781 (DB05871)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00228462
Drug: Seroquel (quetiapine)
RxNorm normalized name: quetiapine Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02919371
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
Trial: NCT02919371
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
Trial: NCT01340547
Drug: palifosfamide-tris
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
Trial: NCT00646906
Drug: Aspirin Last
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crossover period Aspirin Last: Subjects will receive acetaminophen at approximately 8 am followed by 81 mg aspirin at approximately 10 am.
Trial: NCT00050648
Drug: Daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1mg/kg medication every other week on the odd week (week 1-13).
Trial: NCT00050648
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
Trial: NCT00050648
Drug: cyclosporine and Daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
Trial: NCT00917527
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
Trial: NCT02931136
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
Trial: NCT01433757
Drug: Ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
Trial: NCT01433757
Drug: Sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
Trial: NCT01632917
Drug: ATX-101 - U.S.
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US ATX-101, 10 mg/mL, one dosing session in the submental area
Trial: NCT01632917
Drug: ATX-101 - EU
RxNorm normalized name: chlorine dioxide
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU ATX-101, 10 mg/mL, one dosing session in the submental area
Trial: NCT02840240
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
Trial: NCT01508195
Drug: Canagliflozin tablets
RxNorm normalized name: Canagliflozin Tablets
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
Trial: NCT01348607
Drug: methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01348607
Drug: modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03064633
Drug: dexamethasone 8 mg
RxNorm normalized name: dexamethasone 8 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.